Interim Results – Half Year End 30 September 2017

Company Announcement
29 November 2017
PACIFIC EDGE FY18 INTERIM RESULTS
Results for the six months to 30 September 2017

Performance snapshot

Increase in Revenue
Year on year increase in operating revenue, up 41% from 1H17
to $4.2m
Increase in Tests

Laboratory throughput up 26% on 1H17 to 7,107 tests
Reduction in Operating Expenditure
Total operating expenses reduced to $13.5m, a reduction of
11% on 1H17
Reduction in Net Loss
Reported loss of $8.9m for the six months, a reduction of 23%
on the loss in 1H17



Interim Results Commentary

Cancer diagnostics company, Pacific Edge Limited (NZX: PEB) has delivered a strong first half, year on year increase
in revenue as it continues to build momentum and target large scale customers in the United States and other
markets.

Total revenue for 1H18 was up 27% on the prior comparative period to $4.9m, and included operating revenue of
$4.2m which was up 41% on 1H17. A strong second half of the year is expected in line with normal trends
1
.


1
The first half of the financial year is traditionally softer for Pacific Edge, due to the USA summer holiday period and also as it
is usually before Americans with private health insurance reach their deductible level (the amount a patient must pay before
their insurance kicks in).

Company Announcement
29 November 2017
Laboratory throughput, which includes both commercial sales and tests from User Programmes, increased to 7,107
tests, up 26% on 1H17. This has had a corresponding effect on receivables which have increased in line with the
higher test numbers. Lab Throughput is an important metric for Pacific Edge as it reflects the increasing trial and
adoption of Cxbladder by key urologists and healthcare providers.

Total operating expenses reduced to $13.5m, a reduction of 11% on 1H17 which included expenses related to the
winding up of the Employee Incentive Scheme. Net operating cashflows remain in line with expectations and were
$(10.2)m for the six months (1H17: $9.1m). Receipts in 1H18 reflect the number of tests completed in 2H17 due
to the time lag between completion of tests and the receipt of payment from relevant US payers. This time to cash
receipt will improve when the company is included in the Centers for Medicare and Medicaid Services (CMS) Local
Coverage Determination (LCD).

In line with the conservative approach taken by Board at the end of the FY17 year, bad debts of $0.7m and doubtful
debts of $0.8m have been recognised in 1H17, to account for additional long standing receivables. Pacific Edge is
striving to obtain the necessary insurance contract coverages to guarantee terms of payment from insurance payers
and will seek recovery of payments that have been written off, once insurance coverage is obtained. Pacific Edge is
no longer accruing revenue for tests completed for CMS patients. CMS tests account for approximately 50% of
current Laboratory Throughput, indicating a significant number of tests which will be added to the annual revenue
when the company receives its expected LCD.

For the six months ended 30 September 2017, Pacific Edge reported a net loss of $8.9m, a reduction of 23% on the
$11.6m reported in 1H17.

Pacific Edge had $4.0m in cash and cash equivalents at 30 September 2017 and, following the completion of the
recent capital raising on 10 November 2017, has received the additional $21.3m of capital raised.

Pacific Edge’s primary focus remains on growing revenue by commercialising large scale customers, including the
Veterans Administration (VA), Kaiser Permanente and the CMS in the US, as well as District Health Boards (DHBs)
in New Zealand and other large healthcare providers. While the administration and clinical sign off for commercial
use by these large organisations can be long and time consuming, the scale and long term sales opportunity they
present is significant.

A Federal Supply Schedule was received in 2017, allowing access to the VA, and early sales are starting to be seen
from two of the initial five clinics being targeted. The company’s focus has now expanded to include a number of
the larger VA centres.

Commercial negotiations are progressing positively with Kaiser Permanente, following the compelling and positive
results of the large scale evaluation of Cxbladder User Programme in late 2016. Contemporaneously with this,
Pacific Edge has been working with Kaiser’s staff on the necessary business elements to ensure that the start-up of
commercial tests can occur expediently following the completion and signing of the agreement.

In addition, Pacific Edge is continuing to work through the process required to gain inclusion in the LCD from the
CMS. Once this is received, it will enable consistent and timely reimbursement for Medicare patients, on normal
CMS payment terms. The inclusion into the LCD and the commensurate pricing negotiation will provide the catalyst
for Pacific Edge to negotiate agreements with other private payers which view the CMS pricing as a benchmark,
providing further certainty on price and payment terms for Pacific Edge.

Company Announcement
29 November 2017

New Zealand urologists continue to lead the way globally in the adoption and commercial use of Pacific Edge’s
novel molecular diagnostic tests, with the majority of the large DHBs now offering their patients access to
Cxbladder. The recent global first was the signing by Mid-Central DHB to make the full suite of Cxbladder tests
available to their patients. While a good infrastructure is now in place in Australia, uptake has been slower than in
New Zealand and Pacific Edge is working closely with its distribution partner, Tolmar Australia, to drive adoption.
The investigations into South East Asia continue to progress, with three User Programmes in large scale hospitals
now running in Singapore, of which one is expected to transition to a commercial customer in the near future.
Additional User Programmes are expected to commence in the second half of the year.

Chairman of Pacific Edge, Chris Gallaher said: “We are working hard to achieve our goal of being cash-flow positive.
The rate that we progress is entirely driven by the contribution to revenue from the large scale customers that we
are targeting and we are working hard to convert these transformational customers into revenue and cash.”

CEO of Pacific Edge, David Darling, said: “There is no doubt that Cxbladder is a breakthrough product – more and
more urologists and healthcare providers are now recognising this and are looking to adopt our products into
clinical use with some of the large public healthcare providers in New Zealand adding Cxbladder to their standard
of care. Momentum is building and the full efforts of everyone in the company are focused on transforming Pacific
Edge into a globally recognised and successful New Zealand business.”

ENDS

For more information contact:

David Darling
Chief Executive Officer, Pacific Edge Ltd
P: +64 (3) 479 5800

OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com
Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and
commercialisation of diagnostic and prognostic tests for better detection and management of cancer. The company is
developing and commercialising its range of Cxbladder bladder cancer tests globally through its wholly owned central
laboratories in New Zealand and the USA. The company’s products have been tested and validated in international multi-centre
clinical studies.

Pacific Edge has three proprietary, novel, accurate, molecular diagnostic products in-market providing actionable results, and
better detection and management of urothelial cancer. Cxbladder Detect and Cxbladder Triage are available through the
company’s dedicated CLIA certified laboratories for customers in New Zealand, Australia and the USA. Cxbladder Monitor
launched in New Zealand in December 2015 and is anticipated being available in the US in 2016.

ABOUT Cxbladder Triage www.cxbladder.com
Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to
accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more
extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of patients
with haematuria and is intended to reduce the need for an expensive and invasive work-up in patients who have a low
probability of having urothelial carcinoma.

Company Announcement
29 November 2017
ABOUT Cxbladder Detect www.cxbladder.com
Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of a
patients’ urine. Cxbladder Detect was launched in 2013 in the USA and is commercially available in New Zealand, Australia and
the USA as a Laboratory Developed Test (LDT) from the company’s CLIA certified laboratories. Cxbladder Detect provides
clinicians with a quick, cost effective and accurate measure of the presence of the cancer as an effective adjunct to cystoscopy.

ABOUT Cxbladder Monitor www.cxbladder.com
Cxbladder Monitor, the third test in the Cxbladder portfolio for urologists, is a proprietary, non-invasive, molecular diagnostic
test that combines genomic biomarkers measured from a small quantity of a patient’s urine, with patient specific clinical factors
to better monitor bladder cancer patients for recurrence. Bladder cancer has a recurrence rate of 50-80% and requires life-
long surveillance. Cxbladder Monitor accurately identifies patients with a prior history of urothelial cancer (UC) whose
Cxbladder Monitor score shows that they have a low probability of recurrent urothelial carcinoma. Cxbladder Monitor is
designed to be used as the preferred adjunct test to cystoscopy in the management of patients for ongoing evaluation of
recurrent bladder cancer.

ABOUT Cxbladder Resolve www.cxbladder.com
Cxbladder Resolve is a proprietary, non-invasive, molecular diagnostic test that combines genomic biomarkers measured from
a small quantity of a patient’s urine, with patient characteristics for the identification of patients who are likely to have
aggressive or more advanced bladder cancer. Cxbladder Resolve, when used as part of the primary evaluation of haematuria
and/or in conjunction with other Cxbladder tests (Triage, Detect), is designed to assist clinicians by accurately identifying
patients with a high probability of having high grade or late stage bladder cancer, for whom alternative or expedited treatment
options may be warranted, or who can be prioritised for further investigation in high throughput settings.

Refer to www.cxbladder.com for more information.

---

INTERIM
FINANCIAL
STATEMENTS
FOR THE SIX MONTHS
ENDED 30 SEPTEMBER 2017

PACIFIC EDGE LIMITED INTERIM REPORT 2017
Note: These Statements are to be read in conjunction with the Notes to the Financial Statements.
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2017
FINANCIAL INFORMATION
STATEMENT OF COMPREHENSIVE INCOME
NOTES
UNAUDITED
SEPT 2017
6 MONTHS
($000)
UNAUDITED
SEPT 2016
6 MONTHS
($000)
AUDITED
MARCH 2017
12 MONTHS
($000)
REVENUE
Operating Revenue 4,225 2,999 8,062
Total Operating Revenue 4,225 2,999 8,062
Other Income 538 498 1,105
Interest Income 81 273 249
Foreign Exchange Gain 8 43 119
Total Revenue and Other Income 4,852 3,813 9,535
OPERATING EXPENSES
Laboratory Operations 618 654 996
Research 1,759 2,470 4,908
Sales and Marketing 1,012 914 1,923
Employee Equity Equivalent Incentive
Scheme
5 - 2,925 2,925
Other Expenses4 10,128 8,160 19,763
Total Operating Expenses 13,517 15,123 30,515
NET (LOSS) BEFORE TAX (8,665) (11,310) (20,980)
Income Tax Expense - - -
(LOSS) FOR THE YEAR AFTER TAX (8,665) (11,310) (20,980)
Translation Foreign Operations (220) (262) (67)
TOTAL COMPREHENSIVE (LOSS) (8,885) (11,572) (21,047)
Earnings per share for profit attributable to the
equity holders of the Company and Group during
the year
Basic and Diluted Earnings per share (0.022) (0.030) (0.055)
2

PACIFIC EDGE LIMITED INTERIM REPORT 2017
Note: These Statements are to be read in conjunction with the Notes to the Financial Statements.
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2017
FINANCIAL INFORMATION
STATEMENT OF CHANGES IN EQUITY
NOTES
SHARE
CAPITAL
FOREIGN
CURRENCY
TRANSLATION
RESERVE
SHARE
BASED
PAYMENTS
RESERVE
RETAINED
EARNINGS
TOTAL
EQUITY
($000)($000)($000)($000)($000)
UNAUDITED 6 MONTHS TO SEPT 2016
Balance as at 31 March 2016 100,012 918 2,404 (73,527) 29,807
(Loss) After Tax - - - (11,310) (11,310)
Other Comprehensive Income - (262) - - (262)
Issue of Share Capital7 2,914 - - - 2,914
Share Based Payment Expense - - 270 - 270
Balance as at 30 September 2016 102,926 656 2,674 (84,837) 21,419
AUDITED 12 MONTHS TO MARCH 2017
Balance as at 31 March 2016 100,012 918 2,404 (73,527) 29,807
(Loss) After Tax - - - (20,980) (20,980)
Other Comprehensive Income - (67) - - (67)
Issue of Share Capital7 11,584 - - - 11,584
Share Based Payment Expense - - 486 - 486
Balance as at 31 March 2017 111,596 851 2,890 (94,507) 20,830
UNAUDITED 6 MONTHS TO SEPT 2017
Balance as at 31 March 2017 111,596 851 2,890 (94,507) 20,830
(Loss) After Tax - - - (8,665) (8,665)
Other Comprehensive Income - (220) - - (220)
Issue of Share Capital7 192 - (18) - 174
Share Based Payment Expense - - 140 - 140
Balance as at 30 September 2017 111,788 631 3,012 (103,172) 12,259
3

PACIFIC EDGE LIMITED INTERIM REPORT 2017
Note: These Statements are to be read in conjunction with the Notes to the Financial Statements.
For and on behalf of the Board of Directors
Director Director
Dated 29th day of November 2017
AS AT 30 SEPTEMBER 2017
FINANCIAL INFORMATION
BALANCE SHEET
NOTES
UNAUDITED
SEPT 2017
6 MONTHS
UNAUDITED
SEPT 2016
6 MONTHS
AUDITED
MARCH 2017
12 MONTHS
($000)($000)($000)
CURRENT ASSETS
Cash and Cash Equivalents 3,997 4,604 6,564
Short Term Deposits - 10,000 8,000
Receivables 8,027 6,427 6,519
Inventory 1,014 600 824
Other Assets 645 580 491
Total Current Assets 13,683 22,211 22,398
NON-CURRENT ASSETS
Property, Plant & Equipment 942 929 837
Intangible Assets 346 273 329
Total Non-Current Assets 1,288 1,202 1,166
TOTAL ASSETS 14,971 23,413 23,564
CURRENT LIABILITIES
Payables and Accruals 2,589 1,994 2,734
Finance Leases 69 - -
Total Current Liabilities 2,658 1,994 2,734
NON-CURRENT LIABILITIES
Finance Leases 54 - -
Total Non-Current Liabilities 54 --
TOTAL LIABILITIES 2,712 1,994 2,734
NET ASSETS 12,259 21,419 20,830
Represented by:
EQUITY
Share Capital7 111,788 102,926 111,596
Accumulated Losses (103,172) (84,837) (94,507)
Share Based Payments Reserve 3,012 2,674 2,890
Foreign Translation Reserve 631 656 851
TOTAL EQUITY 12,259 21,419 20,830
FURTHER INFORMATION:
Return on Assets (%)(59%)(49%)(89%)
Return on Equity (%)(72%)(54%)(101%)
Debt to Equity Ratio (%)22%9%13%
Earnings Per Share (basic and diluted) ($) (0.022) (0.030) (0.055)
Net Tangible Assets Per Share ($) 0.030 0.055 0.051
4

PACIFIC EDGE LIMITED INTERIM REPORT 2017
Note: These Statements are to be read in conjunction with the Notes to the Financial Statements.
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2017
FINANCIAL INFORMATION
STATEMENT OF CASH FLOWS
UNAUDITED
SEPT 2017
6 MONTHS
UNAUDITED
SEPT 2016
6 MONTHS
AUDITED
MARCH 2017
12 MONTHS
($000)($000)($000)
RESTATED
CASH FLOWS TO OPERATING ACTIVITIES
Cash was provided from:
Receipts from Customers & Grant Providers 1,880 2,727 4,616
Interest Received 82 316 732
1,962 3,043 5,348
Cash was disbursed to:
Payments to Suppliers & Employees 12,101 12,170 23,211
Net GST change 46 (31) (25)
12,147 12,139 23,186
Net Cash Flows To Operating Activities (10,185) (9,096) (17,838)
CASH FLOWS TO INVESTING ACTIVITIES:
Cash was provided from:
Short Term Deposits 8,000 10,000 20,000
8,000 10,000 20,000
Cash was disbursed to:
Capital Expenditure on Plant and Equipment 153 130 209
Purchase of Short Term Deposits - - 8,000
Capital Expenditure on Intangible Assets 106 122 270
259 252 8,479
Net Cash Flows To Investing Activities 7,741 9,748 11,521
CASH FLOWS FROM FINANCING ACTIVITIES:
Cash was received from:
Ordinary Shares Issued 94 - 8,750
94 - 8,750
Cash was disbursed to:
Repayment of Finance Leases 17 - -
Issue Expenses - 10 91
17 10 91
Net Cash Flows From Financing Activities 77 (10) 8,659
Net increase (Decrease) in Cash Held (2,367) 642 2,342
Add Opening Cash Brought Forward 6,564 4,160 4,160
Effect of Exchange Rate Changes on Net Cash (200) (198) 62
Ending Cash Carried Forward 3,997 4,604 6,564
Call Accounts 2,551 4,158 5,888
Foreign Currency Call Accounts 1,446 446 676
Total Short Term Deposits 3,997 4,604 6,564
ANZ Term Deposit - 10,000 8,000
Total Short Term Deposits - 10,000 8,000
Total Cash, Cash Equivalents and Short Term Deposits 3,997 14,604 14,564
5

PACIFIC EDGE LIMITED INTERIM REPORT 2017
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2017
NOTES TO THE FINANCIAL STATEMENTS
1 . SUMMARY OF ACCOUNTING POLICIES
The unaudited interim financial statements (“Interim Financial Statements”) presented are
those of Pacific Edge Limited (“Company”) and its subsidiaries (“Group”). The Company is
registered and domiciled in New Zealand for the purpose of developing and commercialising
new diagnostic and prognostic tools for the early detection and management of cancers.
Pacific Edge Diagnostics New Zealand Limited and Pacific Edge Diagnostics USA Limited
manage and operate the laboratories used for the detection of bladder cancer. Pacific
Edge Pty Limited’s purpose is to research and develop the Cxbladder product and other
prognostic tools. Pacific Edge Diagnostics Singapore Pte Limited is assisting with research
and development and will become a sales and marketing entity and Pacific Edge Analytical
Services Limited is a dormant entity.
The Company is a for profit entity, registered in New Zealand under the Companies Act
1993 and is a reporting entity for the purposes of the Financial Markets Conduct Act 2013.
The Company is listed with NZX Limited with its ordinary shares quoted on the NZX Main
Board.
(a) Basis of Preparation of Financial Statements
The Interim Financial Statements for the six months ended 30 September 2017 have been
prepared in accordance with New Zealand Generally Accepted Accounting Practice
(GAAP) and the Financial Markets Conduct Act 2013. They comply with the New Zealand
Equivalents to International Financial Reporting Standards (NZ IFRS) and other guidance as
issued by the External Reporting Board, as appropriate for profit-oriented entities, and with
International Financial Reporting Standards.
The Interim Financial Statements have been prepared in accordance with NZ IAS 34 - Interim
Financial Reporting. In complying with NZ IAS 34, these consolidated Interim Financial
Statements also comply with IAS 34 - Interim Financial Reporting and should be read in
conjunction with the Company’s 2017 Annual Report. The Interim Financial Statements
for the six months ended 30 September 2017 are unaudited. Comparative balances for
30 September 2016 are unaudited, whilst the comparative balances for 31 March 2017 are
audited.
The Interim Financial Statements are prepared on the basis of historical cost, except where
otherwise identified. The presentational currency used in the preparation of the financial
statements is New Zealand dollars and all values are rounded to the nearest thousand
dollars ($000).
(b) Accounting Policies
All significant accounting policies have been applied on a basis consistent with those used in
the audited financial statements of Pacific Edge Limited for the year ended 31 March 2017.
Segment Information
The segments reported in Note 6 have been revised from previous reporting to reflect the
business operations of Commercial and Research. The prior period balances have been
updated to conform with the current period presentation.

6

PACIFIC EDGE LIMITED INTERIM REPORT 2017
(c) Statement of Cash Flows Restatement
An error was found in the 31 March 2017 Statement of Cash Flows during September 2017.
Bad Debts and Doubtful Debts expenses were incorrectly included in the 31 March 2017
Statement of Cash Flows as Operating Cash Expenditure items, rather than being applied
against Operating Cash Receipts. The net effect of this error on 31 March 2017 Net Operating
Cash Flows was nil, but both Receipts from Customers & Grant Providers and Payments to
Suppliers & Employees were overstated in the 31 March 2017 Statement of Cash Flows by
approximately $3.2m. The corrected 31 March 2017 Statement of Cash Flows was released
to NZX on the 27th of September 2017 and the corrected 31 March 2017 amounts are
shown in the Statement of Cash Flows reported in these Interim Financial Statements.
This error had no impact on the 31 March 2017 Statement of Comprehensive Income,
Statement of Changes in Equity, Earnings per Share or the Balance Sheet. This error did not
impact the comparative interim financial statements from 30 September 2016.
(d) Authorisation
The Interim Financial Statements were authorised by the Board of Directors on 29 November
2017. The annual financial statements for the year ended 31 March 2017 were authorised by
the Board of Directors on 24 May 2017.
(e) Audit
The Interim Financial Statements have not been audited. The comparative full year financial
results for the year ended 31 March 2017 have been audited.
(f) Basis of Consolidation
The following entities and the basis of their inclusion for consolidation in these Interim
Financial Statements are as follows:
Ownership Interests
& Voting Rights
Name of Subsidiary
Place of
Incorporation
(or registration)
and Operation
Principal Activity
30 Sept
2017
(%)
30 Sept
2016
(%)
Pacific Edge Diagnostics
New Zealand Limited
New Zealand
Commercial Laboratory
Operation
100100
Pacific Edge Pty LimitedAustralia
Biotechnology Research
& Development
100100
Pacific Edge Diagnostics
USA Limited
USA
Commercial Laboratory
Operation
100100
Pacific Edge Analytical
Services Limited
New ZealandDormant Company100100
Pacific Edge Diagnostics
Singapore Pte Limited
Singapore
Biotechnology Research
& Development
100100
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2016
NOTES TO THE FINANCIAL STATEMENTS
7

PACIFIC EDGE LIMITED INTERIM REPORT 2017
2. INVESTMENT AND ADVANCES IN SUBSIDIARIES
The consolidated Interim Financial Statements incorporate the assets and liabilities and
results of Pacific Edge Diagnostics New Zealand Limited, Pacific Edge Diagnostics USA
Limited, Pacific Edge Diagnostics Singapore Pte Limited, Pacific Edge Analytical Services
Limited and Pacific Edge Pty Limited, all of which are 100% owned by the Company.
Subsidiaries have a 31 March balance date. The investments in and advances to subsidiaries
are eliminated on consolidation in the Group financial statements.
3. DIVIDENDS
The Company does not propose to pay dividends to shareholders similar to previous years.
This policy continues.
4. OTHER EXPENSES
Unaudited
Sept 2017
6 Months
($000)
Unaudited
Sept 2016
6 Months
($000)
Audited
March 2017
12 months
($000)
Other Expenses
Amortisation 90 96 189
Auditors Remuneration - Audit Fees 56 3 70
- Other Assurance Services (refer below) 9 15 15
Bad Debts 674 - 2,635
Doubtful Debts 752 - 613
Depreciation 179 172 353
Directors Fees 137 143 287
Employee Benefits 4,885 4,242 9,384
Employee Share Options 141 270 485
Rental and Lease Expense 544 567 1,067
Other Operating Expenses 2,661 2,652 4,665
Total Other Expenses 10,128 8,160 19,763

Other Assurance Services
Other assurance services performed by the auditor includes; a share registry audit, review
procedures and a review of the Callaghan Innovation Growth Grant claim.
Employee Share Options
Employee Share Options are a non-cash expense.
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2016
NOTES TO THE FINANCIAL STATEMENTS
8

PACIFIC EDGE LIMITED INTERIM REPORT 2017
5. PACIFIC EDGE INCENTIVE PLAN
In March 2011 the Company developed an “Incentive Plan” as a means of providing Key
Persons with the opportunity to participate in the potential increasing profitability of the
Group. The Plan was an Equity Equivalent (EE) Scheme that provides EE Units on the
following terms:
• EE Units are vested to the Participant over a period of 4 years but cannot be redeemed
during the first two years from the date of their issue.
• Each EE Unit has the equivalent value of an ordinary share in the Company.
• Redemption is in cash for the difference between the value of the EE Units at the time
of allocation and their value at the time of redemption.
• The Company must be trading in a cash flow positive condition and the Company’s
share price on the NZX must have reached $1.00 per share.
• A maximum of 25% of a Participant’s vested EE Units can be redeemed in any one year.  
On 30 June 2016 the Board of Directors voted in favour of winding up this scheme. 6,253,000
EE units had been issued at this date of which 5,720,500 had vested. After obtaining an
independent valuation and receiving approval from the EE unit holders to cancel the scheme,
the scheme was cancelled and 5,194,583 shares were issued to employees as consideration
at $0.563 per share. This has been treated as a modification from a cash settled to equity
settled share scheme. The shares were issued with no vesting conditions attached and as no
liability had been recognised for these EE units in previous years, this has resulted in a non-
cash share based payment expense in the corresponding period last year of $2,924,550.
6. SEGMENT INFORMATION
The Chief Executive Officer has determined the operating segments based on reports
reviewed by him that are used to make strategic decisions and considers the business to
have two operating segments at 30 September 2017.
These segments are:
- Commercial: The sales, marketing, laboratory and support operations to run the
commercial businesses worldwide.
- Research: The research and development of diagnostic and prognostic products for
human cancer.
The segment revenue and assets information provided to the Chief Executive Officer for the
reportable segments described above, for the six months ended 30 September 2017, are
shown over the page.

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2017
NOTES TO THE FINANCIAL STATEMENTS
9

PACIFIC EDGE LIMITED INTERIM REPORT 2017
Unaudited - 6 Months
30 September 2017
Commercial
($000)
Research
($000)
Less:
Eliminations
($000)
Total
External
Income
($000)
Income
Product Sales 4,225 - - 4,225
Grant Revenue and Research Rebate - 538 - 538
Other Income 141 296 (348) 89
Total Income 4,366 834 (348) 4,852
Expenses
Expenses 9,236 4,360 (348) 13,248
Depreciation & Amortisation 122 147 - 269
Total Operating Expenses 9,358 4,507 (348) 13,517
Loss Before Tax (4,992) (3,673) - (8,665)
Audited - 12 Months
31 March 2017
Commercial
($000)
Research
($000)
Less:
Eliminations
($000)
Total
External
Income
($000)
Income
Product Sales 8,227 - (165) 8,062
Grant Revenue and Research Rebate - 1,105 - 1,105
Other Income 73 3,224 (2,929) 368
Total Income 8,300 4,329 (3,094) 9,535
Expenses
Expenses 19,336 13,731 (3,094) 29,973
Depreciation & Amortisation 227 315 - 542
Total Operating Expenses 19,563 14,046 (3,094) 30,515
Loss Before Tax (11,263) (9,717) - (20,980)
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2017
NOTES TO THE FINANCIAL STATEMENTS
10

PACIFIC EDGE LIMITED INTERIM REPORT 2017
Unaudited - 6 Months
30 September 2016
Commercial
($000)
Research
($000)
Less:
Eliminations
($000)
Total
External
Income
($000)
Income
Product Sales 2,999 - - 2,999
Grant Revenue and Research Rebate - 498 - 498
Other Income 149 474 (307) 316
Total Income 3,148 972 (307) 3,813
Expenses
Expenses 6,795 8,367 (307) 14,855
Depreciation & Amortisation 112 156 - 268
Total Operating Expenses 6,907 8,523 (307) 15,123
Loss Before Tax (3,759) (7,551) - (11,310)
Pacific Edge Diagnostics New Zealand Limited and Pacific Edge Diagnostics USA Limited have
carried out the analysis of Cxbladder tests for Pacific Edge Limited as part of the Company’s
user programmes with customers in New Zealand, Australia and the USA respectively. User
Programmes are an important component of the adoption process for Cxbladder.
The revenue from intercompany transactions has been eliminated on consolidation of Group
results.
Segment assets and liabilities information:
Unaudited
As at 30 September 2017
Commercial
($000)
Research
($000)
Total
($000)
Total Assets 9,105 5,865 14,970
Total Liabilities 1,570 1,142 2,712
Audited
As at 31 March 2017
Commercial
($000)
Research
($000)
Total
($000)
Total Assets 7,967 15,597 23,564
Total Liabilities 1,419 1,315 2,734
Unaudited
As at 30 September 2016
Commercial
($000)
Research
($000)
Total
($000)
Total Assets 6,807 16,606 23,413
Total Liabilities 1,139 855 1,994
The amounts provided to the Chief Executive Officer with respect to total assets are
measured in a manner consistent with that of the Interim Financial Statements. These assets
are allocated based on the operation of the segment and the physical location of the asset.
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2017
NOTES TO THE FINANCIAL STATEMENTS
11

PACIFIC EDGE LIMITED INTERIM REPORT 2017
7. SHARE CAPITAL
Shares
(000)
Unaudited
Sept 2017
6 Months
($000)
Unaudited
Sept 2016
6 months
($000)
Audited
March 2017
12 months
($000)
Opening Balance 399,271 111,596 100,012 100,012
New Issues 433 192 2,924 11,674
Share Capital Before Issue Expenses 399,704 111,788 102,936 111,686
Less: Issue Expenses - - (10) (90)
Closing Balance 399,704 111,788 102,926 111,596
As at 30 September 2017, there was 399,704,401 Ordinary Shares on issue (March 2017:
399,271,161 and September 2016: 381,738,061).
All fully paid shares in the Company have equal voting rights and equal rights to dividends.
All Ordinary Shares are fully paid and have no par value.
8. RECONCILIATION OF CASH USED FROM OPERATING ACTIVITIES WITH
OPERATING NET LOSS
Unaudited
Sept 2017
6 Months
($000)
Unaudited
Sept 2016
6 months
($000)
Audited
March 2017
12 months
($000)
Restated
Net Loss for the Period (8,665) (11,310) (20,980)
Add Non Cash Items:
Depreciation 180 172 353
Amortisation 90 96 189
Movement in share based payments reserve 122 270 485
Bad Debts 674 - 2,635
Doubtful Debts 752 - 613
Issue of Employee Incentive Scheme Shares 97 2,924 2,925
Effect of exchange rates on net cash (9) (42) (120)
Total Non Cash Items 1,906 3,420 7,080
Add Movements in Other Working Capital items:
Decrease (Increase) in Receivables and Other Assets (3,091) (784) (4,032)
(Increase) in Inventory (190) 107 (116)
Increase (Decrease) in Payables and Accruals (145) (529) 210
Total Movement in Other Working Capital (3,426) (1,206) (3,938)
Net Cash Flows to Operating Activities (10,185) (9,096) (17,838)
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2017
NOTES TO THE FINANCIAL STATEMENTS
12

PACIFIC EDGE LIMITED INTERIM REPORT 2017
9. CONTINGENT LIABILITIES
There were no known contingent liabilities at 30 September 2017 (March 2017: Nil and
September 2016: Nil). The Company and Group have not granted any securities in respect
of liabilities payable by any other party whatsoever.
10. CAPITAL COMMITMENTS
There are no capital commitments at 30 September 2017 (March 2017: Nil and September
2016: Nil).
11. SUBSEQUENT EVENTS
On the 11th of October 2017, the Company announced a 1 for 6 rights issue of ordinary
shares. This rights issue was fully underwritten by First NZ Capital Securities Limited and
raised $21.3m. The proceeds after deduction of costs were paid into the Company bank
accounts on 15 November 2017.
12. GOING CONCERN
While the Company continues to incur operating losses, the Company remains solvent and
continues to meet its debts as they fall due. The cash flows are a critical part of ensuring the
business continues to operate in line with the business strategy adopted by the Directors.
In preparing the Interim Financial Statements, the Directors have applied the principles of
going concern on the basis that current cash reserves and its ability to generate cash will
be sufficient to meet its debts as they fall due for a minimum of 12 months from signing the
Interim Financial Statements. Given there is uncertainty of future cash flows at the date of
signing these financial statements, a material uncertainty exists at that date.
13. REPORTS TO SHAREHOLDERS
The shareholder has a right to receive from the Company, free of charge, a copy of the
interim report if the shareholder, within 15 working days of receiving the notice, makes a
request to the Company to receive a copy of the interim report.
The interim report is available online. An electronic copy can be accessed by
visiting: www.nzx.com – ticker code (PEB) or www.pacificedge.co.nz or by contacting:
investors@pacificedge.co.nz
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2017
NOTES TO THE FINANCIAL STATEMENTS
13

87 St David Street, PO Box 56, Dunedin, New Zealand
P +64 3 479 5800 F +64 3 479 5801
www.pacificedgedx.com

---

NZX APPENDIX 1 RELEASE
This document relates to Pacific Edge Limited’s
(“the Company”) financial results for the half-year
ended 30 September 2017, released to NZX on
29 November 2017.
The results are presented unaudited.

PACIFIC EDGE LIMITED NZX APPENDIX 1 RELEASE 2017
2
PACIFIC EDGE LIMITED
RESULTS FOR ANNOUNCEMENT TO THE MARKET
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2017
AMOUNT
($000)
PERCENTAGE
CHANGE
Revenue from ordinary activities, made up of: ($000)
4,76336%
- Product Sales and Licence Fees 4,225 41% Increase
- Grants Received and Research Rebates 538 8% Increase
Profit (loss) from ordinary activities after tax attributable to security holders (8,665)-23%
Net profit (loss) attributable to security holders (8,665)-23%
REPORTING PERIOD: SIX MONTHS ENDED 30 SEPTEMBER 2017
PREVIOUS REPORTING PERIOD: SIX MONTHS ENDED 30 SEPTEMBER 2016
INTERIM/ FINAL DIVIDEND
The Company does not propose to pay dividends to shareholders.
NET TANGIBLE ASSETS
Net tangible assets per share is 3 cents per share at 30 September 2017
(30 September 2016: 5 cents per share).
COMMENTARY ON RESULTS
For commentary on the results please refer to the commentary on the related NZX release.
FINANCIAL INFORMATION
The Appendix 1 Release should be read in conjunction with the unaudited Interim Financial
Statements for the six months ended 30 September 2017 which have been released together
with this NZX Appendix 1 Release.

PACIFIC EDGE LIMITED NZX APPENDIX 1 RELEASE 2017
3
HALF YEAR ANNOUNCEMENT
The information below is as required by Appendix 1 of the NZX Main Board Listing Rules.
2.1 DETAILS OF THE REPORTING PERIOD AND THE PREVIOUS REPORTING PERIOD
The reporting period is for the six months ended 30 September 2017 (‘current year’)
with the comparative period being for the six months ended 30 September 2016
(‘previous year’).
2.2 INFORMATION PRESCRIBED BY NZX
Refer to “Results for Announcement to the Market”.
2.3 THE FOLLOWING INFORMATION:
(a) A Statement of Financial Performance
Refer to the Interim Financial Statements for the six months ended 30 September 2017.
(b) A Statement of Financial Position
Refer to the Interim Financial Statements for the six months ended 30 September 2017.
(c) A Statement of Cash Flows
Refer to the Interim Financial Statements for the six months ended 30 September 2017.
(d) Details of dividends or distributions and dividend or distribution payments
The Company does not propose to pay dividends to shareholders.
(e) Details of any dividend or distribution reinvestment plans in operation and the
last date for the receipt of an election notice for participation in any dividend or
distribution reinvestment plan
The Company has no dividend reinvestment plan.
(f) Net tangible assets per security
Refer to the Results for Announcement to Market.
(g) Details of entities over which control has been gained or lost during the period
Entities over which control has been lost Nil
Entities over which control has been gained Nil
(h) Details of associates and joint ventures
Nil
3.1 BASIS OF PREPARATION
These Interim Financial Statements for the six months ended 30 September 2017
have been prepared in accordance with New Zealand Generally Accepted Accounting
Practice (NZ GAAP). They comply with NZ IAS 34, Interim Financial Reporting and also
IAS 34.
3.2 ACCOUNTING POLICIES
Refer to Statement of Accounting Policies in the Interim Financial Statements for the
six months ended 30 September 2017.
PACIFIC EDGE LIMITED
HALF YEAR RESULTS ANNOUNCEMENT
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2017

PACIFIC EDGE LIMITED NZX APPENDIX 1 RELEASE 2017
4
3.3 CHANGES IN ACCOUNTING POLICIES
During the six month period ended 30 September 2017, the Company made no changes
to accounting policies.
3.4 AUDIT REPORT
The Interim Financial Statements for the six months ended 30 September 2017 have not
been audited.
3.5 ADDITIONAL INFORMATION
Not applicable.
The Interim Financial Statements were approved by the Board of Directors on
29 November 2017.
Chris Gallaher
Chairman
87 St David Street, PO Box 56, Dunedin, New Zealand
P +64 3 479 5800 F +64 3 479 5801
www.pacificedgedx.com
HALF YEAR ANNOUNCEMENTPACIFIC EDGE LIMITED
HALF YEAR RESULTS ANNOUNCEMENT
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2017